Platform Technology Partners Has $675,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Platform Technology Partners reduced its position in Pfizer Inc. (NYSE:PFEFree Report) by 39.3% in the 4th quarter, HoldingsChannel reports. The firm owned 24,388 shares of the biopharmaceutical company’s stock after selling 15,783 shares during the period. Platform Technology Partners’ holdings in Pfizer were worth $675,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of PFE. GoalVest Advisory LLC lifted its position in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the period. VisionPoint Advisory Group LLC lifted its holdings in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. Tennessee Valley Asset Management Partners bought a new position in Pfizer in the fourth quarter valued at approximately $36,000. DiNuzzo Private Wealth Inc. acquired a new position in Pfizer during the fourth quarter valued at approximately $37,000. Finally, Life Planning Partners Inc bought a new stake in Pfizer during the fourth quarter worth $39,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PFE. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Ten equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $35.86.

Check Out Our Latest Research Report on PFE

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.21 during midday trading on Friday, reaching $28.59. The company’s stock had a trading volume of 27,514,438 shares, compared to its average volume of 41,916,836. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a market capitalization of $162.01 billion, a P/E ratio of -478.75, a PEG ratio of 1.16 and a beta of 0.70. The firm has a 50 day moving average price of $27.48 and a 200-day moving average price of $27.89. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37.

Pfizer (NYSE:PFEGet Free Report) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the business posted $1.23 earnings per share. The business’s quarterly revenue was down 19.5% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 5.88%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.